BOSTON, March 30, 2026 -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not...
Plexxikon, Wyeth PPAR Deal: Up to $372M In Diabetes Bid (BioWorld Today)
News | 11. 01. 2004
Plexxikon
If there’s anxiety lingering after the FDA’s summer ruling about potential cancer toxicity with peroxisome proliferator-activated receptors (PPARs), you wouldn’t know it from Wyeth – which entered a potential $372 mil- lion deal with Plexxikon Inc. to develop treatments for diabetes and metabolic disorders.
